September 18, 2023 Sophia Vida
Breaking News

Oncocyte’s VitaGraftTM Kidney Identifies Transplant Rejection 10 Months Earlier

Interventional study compares VitaGraft to current transplant rejection monitoring protocols Oncocyte’s VitaGraft assay detects antibody-mediated transplant rejection 10 months sooner than commonly used monitoring protocols (p<0.001) IRVINE, CA, September 18, 2023 – Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, today announced the presentation of significant new clinical data at the European Society of Organ Transplant … Continue reading “Oncocyte’s VitaGraftTM Kidney Identifies Transplant Rejection 10 Months Earlier”